GSK plc (LON:GSK)
London · Delayed Price · Currency is GBP · Price in GBX | Market Cap | 75.45B |
| Revenue (ttm) | 32.17B |
| Net Income (ttm) | 5.49B |
| Shares Out | 4.01B |
| EPS (ttm) | 1.33 |
| PE Ratio | 14.15 |
| Forward PE | 10.54 |
| Dividend | 0.61 (3.28%) |
| Ex-Dividend Date | Nov 13, 2025 |
| Volume | 6,553,009 |
| Average Volume | 6,708,366 |
| Open | 1,856.50 |
| Previous Close | 1,858.00 |
| Day's Range | 1,852.00 - 1,880.50 |
| 52-Week Range | 1,242.50 - 1,909.73 |
| Beta | 0.25 |
| RSI | 60.41 |
| Earnings Date | Feb 4, 2026 |
About GSK plc
GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, specialty medicines, and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through Commercial Operations and Total R&D segments. The company offers specialty medicines that include oncology, respiratory/immunology, inflammation, and inhaled medicines for HIV, respiratory eosinophildriven diseases, lupus and lupus nephritis, ovarian cancer, and endometrial cancer. It a... [Read more]
Financial Performance
In 2024, GSK plc's revenue was 31.38 billion, an increase of 3.46% compared to the previous year's 30.33 billion. Earnings were 2.58 billion, a decrease of -47.75%.
Financial StatementsNews
GSK plc (GSK) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
GSK Still Has Room To Run Despite Vaccine Cyclicality
GSK Collaborates with Summit Therapeutics on Cancer Treatment Trial
GSK Collaborates with Summit Therapeutics on Cancer Treatment Trial
Summit Therapeutics Announces Clinical Trial Collaboration with GSK to Evaluate Ivonescimab in Combination with GSK's B7-H3 Antibody Drug Conjugate (ADC)
MIAMI--(BUSINESS WIRE)---- $SMMT--Summit Therapeutics Inc. (NASDAQ: SMMT) today announced it has entered into a clinical trial collaboration with GSK plc (“GSK”, LSE/NYSE: GSK) to evaluate ivonescimab...
AnaptysBio Pushes Back Against Lawsuit Over Cancer Drug Jemperli Royalties
AnaptysBio Inc. (NASDAQ: ANAB) has pushed back against claims that it breached its long-standing licensing deal tied to the cancer drug Jemperli, asking a Delaware court to dismiss what it calls an i...
AnaptysBio seeks partial dismissal in GSK oncology unit dispute over drug royalty
AnaptysBio said on Thursday it filed a partial motion to dismiss a claim by GSK's oncology unit, which alleges the biotech breached their contract, escalating a legal dispute over royalties tied to sa...
Anaptys Files Motion to Dismiss Tesaro's Claim of Anticipatory Breach of Contract in Ongoing Litigation Against Tesaro, a GSK subsidiary
Trial to resolve all claims in the Anaptys and Tesaro/GSK dispute is scheduled for July 14-17, 2026 SAN DIEGO, Jan. 08, 2026 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (NASDAQ: ANAB), a clinical-stage biot...
GSK's Chronic Hepatitis B Drug Meets Goals in Two Late-Stage Studies
GSK's bepirovirsen hit primary endpoints in two phase III trials, boosting hopes for a functional cure in chronic hepatitis B patients.
GSK Licenses Noetik's AI Foundation Models in Anchor Partnership to Transform Cancer Therapeutic Research and Development
SAN FRANCISCO--(BUSINESS WIRE)-- #GSK--GSK licenses Noetik's AI foundation models in anchor partnership to transform cancer therapeutic research and development.
GSK/Ionis Partnered Investigational Drug Shows Strong Results In Large Hepatitis B Studies
Ionis Pharmaceuticals Inc . (NASDAQ: IONS) partner GSK Plc (NYSE: GSK) on Wednesday shared data from two pivotal Phase 3 studies, B-Well 1 and B-Well 2, of bepirovirsen, an investigational antisense...
GSK/Ionis Partnered Investigational Drug Shows Strong Results In Large Hepatitis B Studies
Ionis Pharmaceuticals Inc. (NASDAQ: IONS) partner GSK Plc (NYSE: GSK) on Wednesday shared data from two pivotal Phase 3 studies, B-Well 1 and B-Well 2, of bepirovirsen, an investigational antisense ol...
GSK's Promising Phase III Trial Results for Hepatitis B Treatment
GSK's Promising Phase III Trial Results for Hepatitis B Treatment
GSK Simplifies Shingrix Vaccine with Prefilled Syringe Approval
GSK Simplifies Shingrix Vaccine with Prefilled Syringe Approval
GSK Scores Phase III Win in Hep B(edit)
GSK Scores Phase III Win in Hep B(edit)
GSK Reports Positive Results from Hepatitis B Trials
GSK Reports Positive Results from Hepatitis B Trials
GlaxoSmithKline reports phase III success for bepirovirsen in chronic hepatitis B
European Commission approves Shingrix in a prefilled syringe, simplifying vaccine prep for healthcare professionals.
GSK (GSK) Reports Promising Phase 3 Results for Hepatitis B Treatment
GSK (GSK) Reports Promising Phase 3 Results for Hepatitis B Treatment
GSK: European Commission Approves Shingrix In Prefilled Syringe
(RTTNews) - GSK plc (GSK, GSK.L) announced the European Commission's approval of Shingrix in a prefilled syringe. The current vaccine presentation comprises two vials. The company said the new prefill...
Ionis partner GSK announces positive topline results from B-Well 1 and B-Well 2 Phase 3 studies for bepirovirsen, a potential first-in-class medicine for chronic hepatitis B
– Primary endpoint met in both trials – – Bepirovirsen demonstrated a statistically significant and clinically meaningful functional cure rate – – Chronic hepatitis B (CHB) accounts for ~56% of liver ...
GSK's chronic hepatitis B treatment meets main goal in key studies
GSK's experimental drug to treat chronic hepatitis B infection met the main goals in two closely watched studies, the drugmaker said on Wednesday, bringing the company a step closer to making a functi...
GSK Downgraded to Underweight by Barclays Today | GSK Stock News
GSK Downgraded to Underweight by Barclays Today | GSK Stock News
FENI, BTI, GSK, HSBC: Large Inflows Detected at ETF
Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the Fidelity Enhanced International ETF (Symbol: FENI) where we have detec...
GSK Wins Japan Approval for Exdensur(edit)
GSK Wins Japan Approval for Exdensur(edit)